Cargando…
Prediction of hERG inhibition of drug discovery compounds using biomimetic HPLC measurements
The major causes of failure of drug discovery compounds in clinics are the lack of efficacy and toxicity. To reduce late-stage failures in the drug discovery process, it is essential to estimate early the probability of adverse effects and potential toxicity. Cardiotoxicity is one of the most often...
Autores principales: | Stergiopoulos, Chrysanthos, Tsopelas, Fotios, Valko, Klara |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Association of Physical Chemists
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8920097/ https://www.ncbi.nlm.nih.gov/pubmed/35300361 http://dx.doi.org/10.5599/admet.995 |
Ejemplares similares
-
The electric heart of hERG
por: Islas, León D.
Publicado: (2013) -
An Update on the Structure of hERG
por: Butler, Andrew, et al.
Publicado: (2020) -
Mitragynine, an euphoric compound inhibits hERG1a/1b channel current and upregulates the complexation of hERG1a-Hsp90 in HEK293-hERG1a/1b cells
por: Tay, Yea Lu, et al.
Publicado: (2019) -
Stereoselective Blockage of Quinidine and Quinine in the hERG Channel and the Effect of Their Rescue Potency on Drug-Induced hERG Trafficking Defect
por: Yan, Meng, et al.
Publicado: (2016) -
Early identification of hERG liability in drug discovery programs by automated patch clamp
por: Danker, Timm, et al.
Publicado: (2014)